• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Talphera Inc.

    4/17/25 4:30:50 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLPH alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001427925
    ACELRX PHARMACEUTICALS INC
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    TALPHERA, INC.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    TALPHERA, INC.
    Street Address 1 Street Address 2
    1850 GATEWAY DRIVE SUITE 175
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    SAN MATEO CALIFORNIA 94404 650-216-3500

    3. Related Persons

    Last Name First Name Middle Name
    Angotti Vincent J
    Street Address 1 Street Address 2
    1850 Gateway Drive, Suite 175
    City State/Province/Country ZIP/PostalCode
    San Mateo CALIFORNIA 94404
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Dasu Badri P
    Street Address 1 Street Address 2
    1850 Gateway Drive, Suite 175
    City State/Province/Country ZIP/PostalCode
    San Mateo CALIFORNIA 94404
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Asadorian Raffi
    Street Address 1 Street Address 2
    1850 Gateway Drive, Suite 175
    City State/Province/Country ZIP/PostalCode
    San Mateo CALIFORNIA 94404
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Adams Adrian
    Street Address 1 Street Address 2
    1850 Gateway Drive, Suite 175
    City State/Province/Country ZIP/PostalCode
    San Mateo CALIFORNIA 94404
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Aslam Shakil
    Street Address 1 Street Address 2
    1850 Gateway Drive, Suite 175
    City State/Province/Country ZIP/PostalCode
    San Mateo CALIFORNIA 94404
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Broadfoot Jill
    Street Address 1 Street Address 2
    1850 Gateway Drive, Suite 175
    City State/Province/Country ZIP/PostalCode
    San Mateo CALIFORNIA 94404
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Bozilenko Marina
    Street Address 1 Street Address 2
    1850 Gateway Drive, Suite 175
    City State/Province/Country ZIP/PostalCode
    San Mateo CALIFORNIA 94404
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hoffman Stephen J
    Street Address 1 Street Address 2
    1850 Gateway Drive, Sutie 175
    City State/Province/Country ZIP/PostalCode
    San Mateo CALIFORNIA 94404
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Wan Mark
    Street Address 1 Street Address 2
    1850 Gateway Drive, Suite 175
    City State/Province/Country ZIP/PostalCode
    San Mateo CALIFORNIA 94404
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Jain Abhinav
    Street Address 1 Street Address 2
    1850 Gateway Drive, Suite 175
    City State/Province/Country ZIP/PostalCode
    San Mateo CALIFORNIA 94404
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
    X Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-04-02    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
    X Yes    No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    BTIG, LLC 122225
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    350 Bush Street, 9th Floor
    City State/Province/Country ZIP/Postal Code
    San Francisco CALIFORNIA 94104
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
    X All States
       Foreign/non-US

    Recipient
    Recipient CRD Number    None
    A.G.P./Alliance Global Partners 8361
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    590 Madison Ave., 28th Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
    X All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $15,000,000 USD
    or    Indefinite
    Total Amount Sold $4,920,000 USD
    Total Remaining to be Sold $10,080,000 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    11

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $1,050,000 USD
    X Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    TALPHERA, INC. /a/ Raffi Asadorian Raffi Asadorian Chief Financial Officer 2025-04-17

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $TLPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLPH

    DatePrice TargetRatingAnalyst
    1/28/2025$4.00Buy
    Rodman & Renshaw
    More analyst ratings

    $TLPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

      SAN MATEO, Calif., May 7, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2025 financial results after market close on Wednesday, May 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link post

      5/7/25 4:05:00 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025 Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through target completion of the NEPHRO study in the fourth quarter of 2025 Conference call and webcast to be held Monday, March 31, 2025 at 4:30 pm ET SAN MATEO, Calif., March 31, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and

      3/31/25 4:05:00 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

      The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled Talphera believes the NEPHRO CRRT study should be completed by the end of 2025 Existing investors, Nantahala Capital and Rosalind Advisors led the capital commitment priced at-the-market as defined by Nasdaq rules $4.925 million in gross proceeds at first closing with the potential to receive an additional $9.85 million across two $4.925 million tranches upon achieving certain patient enrollment milestones Cash and investments at December 31, 2024 of $8.9 million, together with the expected proceeds from the financing o

      3/31/25 8:30:00 AM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Aslam Shakil was granted 15,000 units of Commom Stock, increasing direct ownership by 40% to 52,695 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      4/3/25 4:31:19 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Engineering Officer Dasu Badri N was granted 15,000 shares, increasing direct ownership by 56% to 42,011 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      4/3/25 4:30:21 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Asadorian Raffi was granted 15,000 shares, increasing direct ownership by 47% to 47,214 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      4/3/25 4:29:17 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $125,000 worth of shares (213,310 units at $0.59) and was granted 61,000 shares, increasing direct ownership by 149% to 474,769 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      4/3/25 4:28:23 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Aslam Shakil bought $6,038 worth of shares (5,695 units at $1.06), increasing direct ownership by 18% to 37,695 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      2/26/25 6:52:05 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $3,200 worth of shares (5,000 units at $0.64), increasing direct ownership by 2% to 208,066 units (SEC Form 4)

      4 - TALPHERA, INC. (0001427925) (Issuer)

      12/6/24 6:05:05 AM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLPH
    SEC Filings

    See more
    • SEC Form EFFECT filed by Talphera Inc.

      EFFECT - TALPHERA, INC. (0001427925) (Filer)

      5/13/25 12:15:21 AM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B7 filed by Talphera Inc.

      424B7 - TALPHERA, INC. (0001427925) (Filer)

      5/12/25 5:18:22 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Talphera Inc.

      S-3 - TALPHERA, INC. (0001427925) (Filer)

      5/2/25 5:12:15 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Talphera with a new price target

      Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00

      1/28/25 7:17:45 AM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLPH
    Financials

    Live finance-specific insights

    See more
    • Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

      SAN MATEO, Calif., May 7, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2025 financial results after market close on Wednesday, May 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link post

      5/7/25 4:05:00 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025 Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through target completion of the NEPHRO study in the fourth quarter of 2025 Conference call and webcast to be held Monday, March 31, 2025 at 4:30 pm ET SAN MATEO, Calif., March 31, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and

      3/31/25 4:05:00 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

      SAN MATEO, Calif., March 26, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on

      3/26/25 4:38:00 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)